Skip to main content
Quest Diagnostics

Performance of Noninvasive Prenatal Screening to Identify 22q11.2 Deletion Syndrome: Experience of a Commercial Laboratory

ISPD 2026

International Society for Prenatal Diagnosis

30th International Conference on Prenatal Diagnosis and Therapy

June 7-9, 2026, Virtual

Poster presentation: Performance of Noninvasive Prenatal Screening to Identify 22q11.2 Deletion Syndrome: Experience of a Commercial Laboratory

Authors: Tessa Niemchak, Julia Wilkinson

Medical Specialty: Genetics, Women's health

Related content

Audio Podcast
Insights into successful family planning: A diagnostics perspective
By: Damian “Pat” Alagia, III, MD, MS, MBA, FACS, FACOG
Audio Podcast
Discovering Prenatal Genetics
On-Demand Webinar
The Link Between Reproductive Abnormalities and Cardiometabolic Conditions
Publication
Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing
Test FAQ
QNatal Advanced
Test FAQ
Chromosome Analysis Chorionic Villus Sample
Publication
Factors That Influence Genetic Counselors' Professional Identity-A Qualitative Study
Publication
AI'm Here to Help: Enhancing Laboratory Genetic Counseling with Artificial Intelligence

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.